Ionis Pharmaceuticals (IONS) Receivables (2009 - 2017)

Ionis Pharmaceuticals' Receivables history runs 9 years deep, the most recent figure standing at $125.9 million for Q4 2017.

• In Q4 2017, Receivables rose 16.54% year-over-year to $125.9 million; the TTM figure through Dec 2017 stood at $125.9 million (up 16.54% YoY), while the FY2017 annual figure was $125.9 million, up 16.54% from the prior year.
• Receivables for Q4 2017 stood at $125.9 million, up from $42.9 million in the prior quarter.
• The five-year high for Receivables was $125.9 million in Q4 2017, with the low at $746000.0 in Q2 2016.
• The 5-year median for Receivables is $12.0 million (2013), against an average of $28.7 million.
• The sharpest annual moves came in 2015 and 2017: Receivables slumped 93.06% in 2015, then surged 6684.85% in 2017.
• Ionis Pharmaceuticals' Receivables stood at $11.1 million in 2013, then plunged by 64.84% to $3.9 million in 2014, then surged by 190.96% to $11.4 million in 2015, then surged by 851.42% to $108.0 million in 2016, then grew by 16.54% to $125.9 million in 2017.
• Business Quant data shows IONS's Receivables at $125.9 million in Q4 2017, $42.9 million in Q3 2017, and $50.6 million in Q2 2017.